Pathophysiology and targeted treatment of cholesterol crystal embolism and the related thrombotic angiopathy

Chongxu Shi,Elmina Mammadova‐Bach,Cong Li,Dong Liu,Hans‐Joachim Anders
DOI: https://doi.org/10.1096/fj.202301316R
2023-09-09
The FASEB Journal
Abstract:Cholesterol crystal (CC) embolism is a complication of advanced atherosclerotic plaques. It is primarily induced by anticoagulants and thrombolytic interventions and vascular surgical procedures. The main approach to CC embolism is primary prophylaxis in patients at risk by stabilizing atherosclerotic plaques (statin therapy) and avoiding unnecessary catheter interventions. Platelet aggregation inhibitors and anticoagulants may reduce the risk of vascular occlusions in case CC embolism occurs. Furthermore, life style controlling is another useful way to prevent atherosclerosis and CC embolism. Cholesterol crystal (CC) embolism is a complication of advanced atherosclerotic plaques located in the major arteries. This pathological condition is primarily induced by interventional and surgical procedures or occurs spontaneously. CC can induce a wide range of tissue injuries including CC embolism syndrome, a spontaneous or intervention‐induced complication of advanced atherosclerosis, while treatment of CC embolism has remained empiric. Vascular occlusions caused by CC embolism may exceed the ischemia tolerance of many tissues, particularly when small arteries are affected. The main approach to CC embolism is primary prophylaxis in patients at risk by stabilizing atherosclerotic plaques and avoiding unnecessary catheter interventions. During CC embolism, the use of platelet inhibitors to avoid abnormal activation and aggregation and anticoagulants may reduce the risk of vascular occlusions and tissue ischemia. This probably explains the relatively low prevalence of clinical manifestations of CC embolism, which are frequently found in autopsy studies. In this review, we summarized the current knowledge on the pathophysiology of CC embolism syndrome deriving from clinical observations and experimental mouse models. Furthermore, we described the risk factors of CC embolism in humans as well as the experimental studies based on empiric treatments. We also discuss potential therapeutic interventions based on recent experimental data and emerging drug options evolving from other research domains. Given the substantial unmet medical need to improve the outcomes of CC embolism, the identification of effective treatment strategies is urgently needed.
What problem does this paper attempt to address?